Does VELAGLUCERASE ALFA Cause Poor venous access? 57 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 57 reports of Poor venous access have been filed in association with VELAGLUCERASE ALFA (VPRIV). This represents 3.3% of all adverse event reports for VELAGLUCERASE ALFA.
57
Reports of Poor venous access with VELAGLUCERASE ALFA
3.3%
of all VELAGLUCERASE ALFA reports
1
Deaths
23
Hospitalizations
How Dangerous Is Poor venous access From VELAGLUCERASE ALFA?
Of the 57 reports, 1 (1.8%) resulted in death, 23 (40.4%) required hospitalization.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VELAGLUCERASE ALFA. However, 57 reports have been filed with the FAERS database.
What Other Side Effects Does VELAGLUCERASE ALFA Cause?
Inappropriate schedule of product administration (197)
Product dose omission issue (188)
Covid-19 (163)
Fatigue (136)
Death (108)
Fall (104)
Pyrexia (101)
Malaise (98)
Weight increased (89)
Headache (88)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which VELAGLUCERASE ALFA Alternatives Have Lower Poor venous access Risk?
VELAGLUCERASE ALFA vs VELCADE
VELAGLUCERASE ALFA vs VELETRI
VELAGLUCERASE ALFA vs VELIPARIB
VELAGLUCERASE ALFA vs VEMURAFENIB
VELAGLUCERASE ALFA vs VENETOCLAX